GO HERE FOR MORE www.newsweek.com/russia-cancer-vaccine-enteromix-claims-trials-2126451
[image: Cancer and vaccine therapy 3d illustration]
Russia has reported that its cancer vaccine “Enteromix” has completed preclinical trials—demonstrating both safety and high efficacy.
Veronika Skvortsova, head of the Russian Federal Medical-Biological Agency (FMBA), made the announcement on Saturday at the Eastern Economic Forum (EEF) in Vladivostok, according to a report by Russian news agency TASS.
“The research spanned several years, with the last three dedicated to mandatory preclinical studies,” Skvortsova reportedly said. “The vaccine is now ready for use; we are awaiting official approval.”
Skvortsova is said to have emphasized that preclinical results confirmed the vaccine’s safety, even with repeated administration, and significant effectiveness.
Researchers observed reductions in tumor size and slowed tumor progression—ranging from 60 to 80 percent—depending on disease characteristics. Studies also indicated increased survival rates attributable to the vaccine.
Various media reports also suggest that the vaccine has shown 100 percent efficacy in preclinical trials, although *Newsweek *has been unable to verify this claim.
The initial target for the vaccine will be colorectal cancer, according to the TASS report.
“Promising progress” has also been made in developing vaccines for the aggressive brain cancer glioblastoma and specific types of melanoma, including ocular melanoma, —with such at “advanced stages of development”—the agency said.
[image: Cancer and vaccine therapy 3d illustration]
Russia has reported that its cancer vaccine “Enteromix” has completed preclinical trials—demonstrating both safety and high efficacy.
Veronika Skvortsova, head of the Russian Federal Medical-Biological Agency (FMBA), made the announcement on Saturday at the Eastern Economic Forum (EEF) in Vladivostok, according to a report by Russian news agency TASS.
“The research spanned several years, with the last three dedicated to mandatory preclinical studies,” Skvortsova reportedly said. “The vaccine is now ready for use; we are awaiting official approval.”
Skvortsova is said to have emphasized that preclinical results confirmed the vaccine’s safety, even with repeated administration, and significant effectiveness.
Researchers observed reductions in tumor size and slowed tumor progression—ranging from 60 to 80 percent—depending on disease characteristics. Studies also indicated increased survival rates attributable to the vaccine.
Various media reports also suggest that the vaccine has shown 100 percent efficacy in preclinical trials, although *Newsweek *has been unable to verify this claim.
The initial target for the vaccine will be colorectal cancer, according to the TASS report.
“Promising progress” has also been made in developing vaccines for the aggressive brain cancer glioblastoma and specific types of melanoma, including ocular melanoma, —with such at “advanced stages of development”—the agency said.
THE NEWS FROM THESE LINKS ARE DECIDED TO BE ACCUARATE OR NOT BY YOU NOT BY THE PROPHETIC NEWS SERVICE by MESSIAH’S BRANCH which is an independent NEWS & RESEARCH MINSITRY FUNDED only by your kind donations, ANY SIZE DONATION HELPS GREATLY, Please go here to donate! prophecyhour.com/donations/ WE ALSO HAVE A MISSION CHURCH FOUND HERE wichitahomeless.com/